News

Bortezomib, which will be marketed under the brand name Vortemyel, is the first therapeutic proteasome inhibitor anticancer drug, used to treat multiple myeloma and mantle cell lymphoma. Following

The Legionella bacteria was identified at the plant’s self-standing cooling tower during the company’s routine testing at the site. The company had ceased all operations at the North

CIDP is characterized by progressive weakness and impaired sensory function in the legs and arms. GL-2045, a recombinant Intravenous Immune Globulin (IVIG)-mimetic, received the orphan drug status for

Both are a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. The drug is the first to be approved by the FDA to

Earlier this year, Cisatracurium Besylate, the generic equivalent of Nimbex, was approved by the US Food and Drug Administration (FDA). The company specializes in lifesaving medicines and technologies

These autoimmune disorders include psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis, as well as numerous orphan indications. The company intends to conduct this multiple ascending

B-701 is a new human monoclonal antibody specific for fibroblast growth factor receptor 3 (FGFR3) that is being developed to target FGFR3-positive tumors. The randomized, double-blinded, placebo-controlled, multicenter,

As part of the deal, MedImmune will have exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18 that are

"SOMAmer molecules are a promising new class of drug entities, and we are excited to continue our work with SomaLogic to fully realize that promise," said Takayuki Shiratsuchi,